Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...
Recent advances in genetic testing technology have transformed personal health care from general guidelines to precise, ...
The chemotherapy drugs 5-FU and capecitabine could harm or kill you if you have a variant in the DPYD gene. Request genetic testing before you take these drugs.
Genetic testing could lower the risk of adverse drug reactions for thousands of patients with cancer
A new study led by Genomics England and Queen Mary University of London estimates that genetic testing could identify ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business a ...
Four free home Covid-19 antigen tests are available to order at COVIDTests.gov, part of the seventh round of the federal government’s test-distribution program. And although this round of test ...
The top genetic tests out right now are from Ancestry and the first in the business, 23andMe. Since they have come out there have been stories of financial struggles and data breaches at 23andMe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback